Related Experiment Video
Updated: Jun 29, 2026
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Triple-negative breast cancer
Gert Stockmans1, Karen Deraedt, Hans Wildiers
1Department of Internal Medicine, University Hospital Gasthuisberg, Herestraat, Leuven, Belgium.
Purpose Of Review:
Triple-negative breast cancer has been of great interest to oncologists because these cancers do not benefit from hormonal therapies or treatments targeted against human epidermal growth factor receptor 2 receptors. The only systemic therapy currently available is chemotherapy, and prognosis remains poor. We would like to describe recent pathological and genetic advancements and their possible implications on the development of new treatment strategies.
Recent Findings:
Increasing pathological and molecular knowledge has led to a better understanding of breast cancer in general. Triple-negative breast cancer, however, remains a heterogeneous subgroup with difficult-to-define subtypes. New targeted therapies are currently being developed and researched.
Summary:
The recent advances in pathological and molecular knowledge have changed the landscape of breast cancer, with triple-negative breast cancer emerging as a pathological and clinical heterogeneous group. The main challenge lies in the development of new tailored treatment strategies for the various subgroups, with receptor kinase inhibition as the most promising new evolution to date. Further trials are needed to validate these new treatment options.
Insights
Triple-negative breast cancer (TNBC) research reveals its complex subtypes and poor prognosis. New targeted therapies, particularly receptor kinase inhibitors, show promise but require further clinical validation.
Area of Science:
- Oncology
- Pathology
- Genetics
Background:
- Triple-negative breast cancer (TNBC) lacks targeted therapies like hormonal or HER2-targeted treatments.
- Chemotherapy is the sole systemic option, with limited efficacy and poor patient outcomes.
- TNBC is a clinically and pathologically heterogeneous cancer subgroup.
Purpose of the Study:
- To review recent pathological and genetic advancements in TNBC.
- To explore the implications of these advances for developing novel treatment strategies.
Main Methods:
- Review of current oncological literature.
- Analysis of pathological and molecular data in TNBC.
- Evaluation of emerging targeted therapies.
Main Results:
- Advances in understanding breast cancer have highlighted TNBC's heterogeneity.
- Subtyping TNBC remains challenging, hindering precise treatment selection.
- Novel targeted therapies, including receptor kinase inhibitors, are under investigation.
Conclusions:
- Recent molecular and pathological insights have reshaped breast cancer understanding, identifying TNBC as a diverse group.
- Developing tailored treatments for distinct TNBC subgroups is a critical challenge.
- Receptor kinase inhibition represents a promising therapeutic avenue, pending further clinical validation.
